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Because of the widespread use of catheter-based
therapies that require femoral artery cannulation,
pseudoaneursym formation has become an ever
increasing problem.1-4 As a result of their associated
risk of rupture, femoral artery pseudoaneurysms have
been treated with operation or, more recently, with
compression therapy.5-9 Ultrasound scan–guided com-
pression therapy has been gaining widespread accep-
tance because it is noninvasive and effective. However,
it is often quite painful, time consuming, and occa-
sionally unsuccessful, and it may require additional
attempts at compression or surgical intervention to
repair the arterial injury. The reported overall success
rate for compression has been variable, ranging from
47% to 100%.9,10 To circumvent the shortcomings of
compression therapy, an alternative, minimally invasive
form of treatment for femoral artery pseudoaneurysms
recently has been advocated.11,12
Cope and Zeit13 first described in 1986 the per-
cutaneous injection of thrombin to successfully treat
peripheral artery aneurysms. Walker et al14 in 1987
used thrombin, delivered transluminally, to treat a
false aneurysm of the profunda. The technique was
not used widely, however, until the recent reports of
Liau et al11 and Kang et al,12 which showed the safe
and effective use of percutaneous thrombin injec-
tions in the treatment of femoral artery pseudo-
aneurysms. In both of these studies, the investiga-
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tors used thrombin at a concentration of 1000
U/mL. The purpose of our study was to compare
compression therapy with thrombin injection thera-
py for femoral artery false aneurysm treatment at a
large tertiary care hospital. In addition, because of
the potential risk of native arterial thrombosis, a
lower concentration of thrombin (100 U/mL) was
tested for its effectiveness.
METHODS
All the available records of pseudoaneurysms that
were treated in the vascular laboratory after January
1996 were reviewed. From January 1996 to May
1998, all the femoral artery false aneurysms were
treated initially with ultrasound scan–guided compres-
sion. The persistent aneurysms were repaired with
operation. From May 1998 to April 1999, the patients
underwent initial treatment either with compression
or with thrombin injection on the basis of the prefer-
ence of the vascular surgeon on call that day in the vas-
cular laboratory. The procedure was explained to the
patients, and agreement was given to undergo the
treatment.
Diagnostic ultrasound scanning was performed
with an Acuson 128XP/10 scanner (Acuson, Mou-
tainview, Calif) with a 5-MHz linear array transducer.
The length, width, and depth of the aneurysm were
measured and recorded. The status of the distal pulses
were determined before and after the procedure. Once
the aneurysm was localized, it was either compressed
with the ultrasound scan probe or injected with a
dilute thrombin solution (100 U/mL). The follow-up
ultrasound scans and the pulse examinations were per-
formed 24 to 72 hours after the treatment to evaluate
for thrombosis or recurrence.
A single technician performed compression for 20
minutes at a time or until the patient asked to have the
procedure stopped because of pain. Intravenous opi-
ates were used to alleviate severe discomfort. If the
first compression was unsuccessful, the procedure was
repeated for as long as 1 hour. Patients with treatment
failures on the first compression day were offered a
repeat session the next day at the discretion of the
treating physicians. Anticoagulation therapy was not
halted routinely before compression. More recently
(1998 to 1999), the patients with failed compression
treatments were offered thrombin injection.
Bovine thrombin (100 U/mL) was prepared with
the addition of 10 mL of sterile normal saline solution
to a 1000-unit vial of thrombin powder (Gentrac,
Middletown, Wis). The solution was mixed well,
drawn into a 10-mL syringe, and attached to a 22-
gauge needle. The pseudoaneurysm was localized
with the ultrasound scan transducer, and the skin was
prepared with a povidone-iodine solution (Fig 1A).
With the duplex scan in B mode, the needle was
inserted into the pseudoaneurysm with ultrasound
scan guidance. With the needle tip in the center of the
aneurysm, the thrombin solution was injected until
opacification of the lumen occurred (Fig 1B). The
aneurysm and the femoral vessels then were examined
to ensure the cessation of flow into the false lumen
and the preservation of normal flow in the native ves-
sels. The patients remained at bedrest for 1 hour after
the procedure. This protocol is similar to that described
by Kang et al.12
RESULTS
From January 1996 to April 1998, ultrasound
scan–guided compression therapy was the primary
treatment method used for femoral artery pseudo-
aneurysms in our institution. We initially conducted
Fig 1. Duplex ultrasound scan of right femoral artery
pseudoaneurysm. A, False aneurysm, 3.6 · 2.1 cm. 
B, Same aneurysm thrombosed after injection of 500 units
of thrombin.
A
B
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a retrospective review of the 22 patients (nine men
and 13 women) with 22 pseudoaneurysms that were
treated during this time period to ascertain the effec-
tiveness of this method. The average age in this pop-
ulation was 68.5 years (range, 39 to 85 years). All
the pseudoaneurysms in this group were caused by
cardiac catheterization. Only 13 of the 22 patients
(59%) underwent successful treatment with com-
pression on the first attempt. Four more pseudo-
aneurysms were successfully treated with repeated
treatments on subsequent days, which resulted in an
overall success rate of 77%. On average, the patients
who underwent successful treatment required 40
minutes (range, 10 to 110 minutes) of compression.
Those patients who underwent successful compres-
sion on return visits required an average of 99 min-
utes of compression. Five patients (23%) with persis-
tent aneurysms underwent operative repair.
From May 1998 to April 1999, we began the
evaluation of the use of ultrasound scan–guided
thrombin injection for the treatment of femoral
artery pseudoaneurysms. Thirty-nine patients were
referred for the evaluation of 40 false aneurysms.
Twenty-three patients underwent primary thrombin
injection therapy of their pseudoaneursyms, and 16
patients with 17 pseudoaneurysms underwent com-
pression therapy. Table I depicts the characteristics
between the two groups. Both groups had similar
demographics and aneurysm sizes (P > .2). Most of
the pseudoaneursyms (88%) were caused by cardiac
catherization, and the remainder were related to
femoral artery access for cardiac surgery (6%), arte-
riography (5%), or renal dialysis (1%). Only five of
the 39 patients were systemically anticoagulated
therapy at the time of treatment.
The compression therapy successfully obliterated
only seven of the 17 pseudoaneurysms (41%). The
patients who underwent successful compression ther-
apy required an average of 25 minutes of compres-
sion (range, 5 to 60 minutes). Six patients, whose
compresion therapy failed, underwent successful
treatment with thrombin injection. The remaining
four pseudoaneurysms were repaired with operation.
Of the 23 patients who underwent initial treat-
ment with a thrombin injection, 21 (91%) had 
successful obliteration of the pseudoaneurysm.
Thrombosis occurred within seconds of the throm-
bin injection and required an average of only 300
units (100 to 600 units). The average size of the
pseudoaneuryms that were treated was 3.2 cm.
There was no statistically significant relation be-
tween the size of the aneurysm and the amount of
thrombin injected. Two aneurysms failed to throm-
bose with thrombin injection. One underwent suc-
cessful compression, and the other necessitated
operative repair. The patients in the thrombin group
did not require analgesia or sedation.
For the entire period, 25 of 40 pseudoaneurysms
(63%) were compressed successfully and 27 of 29
(93%) responded to thrombin injection (Table II).
The average time to thrombosis was 37 minutes of
compression versus only seconds in the thrombin
group (P < .01). The total vascular laboratory time
for compression was 59 minutes per patient and 16
minutes per patient for thrombin injection. Three
patients in the compression group reported signifi-
cant pain and requested that the procedure be abort-
ed: no patients in the thrombin group had discom-
fort. No complications were encountered in either
form of treatment.
Cost analysis. An analysis of hospital charges
revealed that the average charges of hospitalization
for those patients who underwent compression ther-
apy ($51,897) and those patients who underwent
thrombin injection therapy ($50,971) were similar.
The time from pseudoaneurysm treatment to dis-
Table II. Comparison of treatment results
between compression and thrombin injection
Thrombin 
Compression injection
Success rate 63% 93%
Time to thrombosis 37 minutes seconds
Vascular laboratory time 59 minutes 16 minutes
Severe pain 3 none
Complications none none
Average facility cost/patient $636 $142
Table I. Patient demographics from May 1998 to
April 1999
Compression Thrombin injection
No. of false aneurysms 17 23
Age (years) 72 68.3
(range, 56 to 82) (range, 22 to 84)
Sex (M:F) 12:5 11:12
Size of aneurysm (cm) 3.1 3.2
(1.5 to 5.7) (1.5 to 4.2)
Anticoagulation therapy
Heparin 2 3
Aspirin 7 9
Etiology
Cardiac catherization 15 18
Renal dialysis catheter 0 1
Cardiac ballon pump 1 3
Arteriography 1 1
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charge also was similar between the two groups (4.5
days vs 4.8 days). This reflects the fact that femoral
artery false aneurysms in our institution typically
occurred in severely ill patients with other major rea-
sons for hospitalization.
However, there was a significant reduction in the
use of vascular laboratory resources, including vas-
cular laboratory technician time, in the injection
group (16 minutes vs 59 minutes). Operating room
use also was markedly lower for the injection group,
with the consideration of a 23% failure rate of com-
pression even after multiple attempts, which necessi-
tated operation. The rate was only 7% for the injec-
tion group. The average calculated cost per patient
for treatment of a pseudoaneurysm was $636 and
$142 for compression and injection therapy, respec-
tively. This cost calculation was made on the basis of
actual hospital costs at our institution for operative
repair of femoral artery false aneurysms, of hourly
cost in the vascular laboratory, and of cost of sup-
plies. These calculations exclude all physician fees.
DISCUSSION
Percutaneous thrombin injection therapy is a rel-
atively new, but very promising, treatment for iatro-
genic femoral artery pseudoaneurysms. We have
found the procedure to be a safe and more effective
treatment method than compression. It also reduces
vascular laboratory time use. Ninety-three percent of
patients underwent successful treatment with throm-
bin injection therapy as compared with 67% of
patients who underwent treatment with compression
therapy. The work in this study confirms the findings
previously reported by Liau et al11 and Kang et al,12
who reported a 100% and 95% success rate with
thrombin injection, respectively. Except for the lower
concentration of thrombin that was used in this
study, the localization and injection protocol we used
was similar to that used by Kang et al.12
The use of a more dilute thrombin solution than
previously reported with similar success rates is encour-
aging. Thrombosis remains fast, and obviously the
higher concentration is not necessary for successful out-
comes. Thrombosis occurred with an average dose of
300 units per patient, which was significantly less than
in the previous report by Kang et al12 of 1000 units per
patient, with some patients receiving 2000 units. Liau
et al11 reported the use of 1000 units in one patient
and 250 units in four other patients in their report of
five patients who underwent successful treatment with
thrombin injection. We believe that this may actually
reduce the potential for complications that involve the
thrombosis of native arteries as suggested with previous
experimental data.15
Native arterial thrombosis is not only a theoreti-
cal consideration. In their initial reports, neither
Kang et al12 nor Liau et al11 reported any significant
procedure-related complications. However, two
instances of brachial artery thrombosis, one in a 10-
month-old child, during attempted treatment of
pseudoaneurysms have since been reported.16,17 We
believe this to be a result of the small size of the
brachial artery and the slower flow especially in the
presence of a concentrated thrombin solution. We
do not agree with the recommendation to use high-
er concentrations of thrombin in the hope of achiev-
ing the injection of a small volume. The area of
injection is never completely accurate because the B-
mode scan can image the reflection off the shaft of
the needle rather than off the tip. With this uncer-
tainty, we believe that an erroneous injection close
to the native artery can be better tolerated when the
solution is more dilute. In addition, the size of the
native artery may be an important factor and throm-
bin injection should be undertaken cautiously in
areas other than the groin. Recently, we opted to
operate on a 7-month-old boy with an expanding 4-
cm femoral artery pseudoaneurysm with a 3-mm
femoral artery because of our concern over the small
size of the child’s artery and the potential risk of
thrombosis.
Although the technique is effective, we also have
encountered two failures in the attempt to treat
aneurysms with thrombin. In both cases, we were not
confident of the exact site of injection. Occasionally,
the aneurysm is too deep or the cavity is too small to
allow easy access for the injection. The localization 
of the needle tip also can be a challenge, especially in
the presence of a large hematoma. Because clotting of
the needle tip also occurs frequently at contact of the
blood with thrombin in the needle, injection at 
the right time might prove unfeasible. These techni-
cal issues will always limit the applicability of the
thrombin injection to all patients.
Compression treatment remains a suitable alter-
native in some cases. Our success rate of 41% in the
most recent time period is not typical because com-
pression was abandoned after only one attempt.
With determination and repeated attempts at com-
pression, the success rate can be increased signifi-
cantly, as we documented with a 77% success rate
from 1996 to 1998.
We began performing ultrasound scan–guided
thrombin injection therapy during the past year.
Soon, with the obvious efficacy and simplicity of the
technique, all the vascular surgeons involved started
performing the procedure and became comfortable
with the recommendation of its use. During the last
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6 months, it has become our preferred initial treat-
ment for all pseudoaneurysms that appear suitable,
and we continue to use compression in the cases in
which the cavity is small, with an anterior simple
neck, and in the cases in which thrombin injection
therapy fails. We thus believe that the two therapeu-
tic methods are complementary. During the past
year, six patients with compression that initially failed
underwent successful treatment with thrombin and
one patient with failed thrombin injection underwent
successful compression. In addition, three patients in
our thrombin group required 3 to 5 minutes of com-
pression to completely seal the neck after thrombin
injection thrombosed the aneurysm cavity. We also
recognize that spontaneous thrombosis can occur in
small pseudoaneurysms (<2 cm), and we continue on
occasion to observe small aneurysms that may be
unsuitable for either treatment.
Despite the absence of complications in our
report, we believe that the risk is real and recom-
mend that a vascular surgeon perform the injection
or be present at the time of the procedure. We sug-
gest that the thrombin be injected slowly and that
the injection be stopped with the first sign of clot
formation. We have not encountered recurrences
but still believe that a follow-up assessment is appro-
priate because a recurrent aneurysm is possible with
its attendant morbidity.
In this study, we were unable to show an overall
significant cost saving in total hospital expenditures
between the two groups because of the large num-
ber of comorbid factors. However, the reduction of
laboratory time used and the rate of operative repair
significantly diminished the cost of treatment of
femoral artery pseudoaneurysm. Though it was not
measured, it is our distinct impression that patient
satisfaction is greatly enhanced.
CONCLUSION
This study confirms that ultrasound scan–guided
thrombin injection of femoral artery pseudoaneu-
rysms is an easy-to-perform, safe, painless, and high-
ly effective procedure. In addition, a low concentra-
tion of thrombin (100 U/mL) can be used for the
successful treatment of femoral artery pseudo-
aneurysms with a decrease in the potential risk of
native artery thrombosis.
We thank Tracey Richardson for her technical assistance.
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Dr R. Clement Darling, III (Albany, NY). I would
like to thank Dr Taylor and his associates for bringing this
interesting new technique to our attention. This retro-
spective study shows us that 23 patients with femoral
artery pseudoaneurysms can undergo successful treatment
with dilute thrombin injection. And the authors compared
this with a group of ultrasound scan–guided compressions
for the same pathology. In 93% of the cases, this worked
well without any complications. And I just have a couple
of questions that I am going to ask about the results.
In the 7% of patients whose treatment failed, what was
the reason for failure? Do you think if you had used a
higher dose of thrombin that you would have any more
success?
Is thrombin injection the primary therapy for all
patients with femoral pseudoaneurysms? Would you
expand this therapy to other pseudoaneurysms? Are there
any contraindications for use of this therapy?
Although you had no complications, are there any side
effects or any complications that you may anticipate about
which we should inform our patients, especially when get-
ting informed consent for this type of procedure?
I guess one more question would be whether there any
patients for whom you would recommend surgery as
opposed to trying thrombin injection or compression first?
Thanks.
Dr Bradley S. Taylor. First, I will address the issue of
the two patients whose treatment failed and why we think
they may have failed. We do not think that it was a failure
of the technique itself, as far as thrombin being efficacious
or not, but rather an issue of needle placement. It is diffi-
cult to see the tip of the needle within the body of the
pseudoaneurysm, particularly when the patient has a large
hematoma or when that pseudoaneurysm is deep in the
thigh. In the two instances in which we failed, we were not
sure that we injected the thrombin within the cavity of the
pseudoaneurysm itself. One of these failures was early in
our experience, and, with time, we became more accus-
tomed to doing the procedure.
Do I think that using a higher dose of thrombin
would be effective? We gave our patients only one dose of
thrombin per injection, and each patient only received one
injection. In the experience of Kang et al,12 19 pseudo-
aneurysms were successfully treated. Fourteen of those
pseudoaneurysms were initially treated with thrombin, but
five of the patients required additional injections of
thrombin and they were then successful. In our series, we
did not give patients second or third doses of thrombin,
but that may have a rule.
Clearly, you do not need to use 1000 units to throm-
bose these pseudoaneurysms. As our study demonstrates, a
lower concentration is sufficient.
As far as the use of this technique for other pseudo-
aneurysms, we have no experience with that. There is a
report in the literature of a pseudoaneurysm of the acces-
sory hepatic artery that was successfully treated with
thrombin. At this time in our laboratory, we are only
going to use it in the groins.
I think that what is more important is to consider the
size of the vessel that the aneurysm is connected to and
that in small arteries it is not a good idea to use thrombin
injection.
It is the primary therapy that is being offered to
patients in our laboratory, in the last 6 months that has
clearly been the case.
You asked about contraindications. I think the most up-
front contraindication is an allergy to thrombin. But very few
patients, if any, will know whether or not they are allergic to
thrombin because the majority of people are not exposed to
it. But it certainly is a consideration, specifically because of
the fact that it is bovine thrombin that we are using.
Clearly, in regard to the side effects and complications,
the main complication that we worry about is occlusion of
the native artery. This includes the last question that you
asked which concerns patients who we opt to undergo
surgery. It is important, as noted in readings in the litera-
ture, that the consideration of the size of the vessel that is
connected to the pseudoaneurysm. The femoral artery in
adults is fairly large and it has a high flow. The two reports
in the literature have both been thrombosis of the brachial
artery, which is a smaller artery, and one report was in a
10-month-old child.
We had a 7-month-old patient a month ago who had
a 4-cm, expanding pseudoaneurysm from a cardiac
catheterization, and the femoral artery was only about 3
mm. In this patient, we opted to operate, despite the fact
that some had raised the issue of administering a thrombin
injection to this child. I think there are two important
points: one is the size of that vessel, but also the fact that
this was an expanding aneurysm, and it was just obviously
safer to operate.
Dr Peter J. Pappas (Newark, NJ). One of the ques-
tions that I have for you is whether there are any pseudo-
aneurysms that you will not inject? We found that, if the
pseudoaneurysm were less than 2 cm, you could just
watch it and it would thrombose on its own, without any
need for compression or injection. So, what has your expe-
rience been with that?
Dr Taylor. For the smaller aneurysms, and specifically
if they are smaller aneurysms that are deep in the thigh, if
they have a lot of hematoma, and if it is difficult to local-
ize where the placement of the needle is, we will use com-
pression. And that is the protocol that we have set up in
the laboratory now.
I agree with you. The placement of the needle is very
important. In the report by Kang et al,17 in which there was
an occlusion of the brachial artery, the authors were trying
to actually inject within the neck and that resulted in
brachial artery thrombosis. That is really where the risk is,
in that the thrombin is not going to be actually put into the
body or the cavity of the pseudoaneurysm but down into
the native vessel. So, I agree with you.
DISCUSSION
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However, to address your question, for the small
aneurysms that are deep in the thigh or for the small
aneurysms that will look as if they would be easy to com-
press, we will go ahead and compress.
Dr John Blebea (Hershey, Pa). I enjoyed your presen-
tation, and I share your enthusiasm. Thrombin injection is
now our preferred treatment of choice for femoral
pseudoaneurysms. I have a couple questions for you.
In your prospective group, you seem to imply that you
were randomizing patients to one therapy versus the
other. However, you had 17 patients in the compression
group and 23 in the thrombin injection group. Were these
patients actually randomized?
I am also struck by your low, 63% success rate for
ultrasound scan–directed compression therapy, which is
lower than the experience of most investigators. Our
biggest attraction to the thrombin injection technique has
been less the higher success rate than the fact that it takes
so long with ultrasound scan compression and that it is
painful to both the technologist and the patient. What was
your success rate in those 17 patients who underwent
prospective treatment versus the 23 patients who you
examined retrospectively?
Second, have you noticed any association between the
size and the length of the pseudoaneurysm pedicle and
your initial success rate with injection? Out of our first 10
patients, two of them did not have initially successful treat-
ment. In both of those cases, there was almost a nonexis-
tent short pedicle neck that required a second injection and
compression with a sandbag to obtain lasting thrombosis.
Finally, we still do not have an answer to the question
that you posed: What is the minimal amount and concen-
tration of thrombin that is required? Indeed, 1000 U/mL
is a high concentration and supratherapeutic. I hesitate,
however, to accept your alternative as being better. If I
understood your presentation correctly, you are using a
concentration of 100 U/mL, and the average amount that
you injected was 300 units per aneurysm. If the average
size of your aneurysms was 3 cm, then the volume of the
thrombin injection will be larger than the volume of many
of the aneurysms that you are treating. I see this as possi-
bly causing the very complication that you are trying to
avoid, intra-arterial thrombin injection, because the inject-
ed volume is greater than the volume of the pseudo-
aneurysm. Such complications may be less dependent on
the concentration of thrombin used and more on the vol-
ume used, because even 100 U/mL is supraphysiologic.
Even though you have gotten away with it in these 23
patients without evident clinical sequelae, what about
administering the same amount of thrombin at a higher
concentration but in smaller volumes?
Dr Taylor. Your first question concerned why we did
not randomize our patients. Obviously, the appropriate
way to look at both of these groups would be to do a ran-
domized, controlled study. However, because of the way
things were set up in the laboratory at that time and
because of the enthusiasm for the procedure at that time,
the patients were not randomized. Instead, they were
essentially offered different therapies. Also, it depended on
who was on call that day or the vascular surgeon who was
available. Therefore, the patients were not randomized.
It was very astute of you to notice our low success rate
from May 1998 to April 1999. Our success rate was high-
er in the 2 years before we began thrombin injection treat-
ment and this brings up an interesting point. In all the
patients who underwent treatment before May 1998, we
had a 77% success rate with compression therapy. This is
compared with the last year in which our success rate was
only about 45% or 44%.
This low success rate may, in fact, be the result of the
new enthusiasm that we have for thrombin injection treat-
ment, in that we are more willing to treat patients with
thrombin injection if we believe that compression therapy
will fail.
We did not measure the size of the pedicles of the
neck. We were achieving a good success rate, and only two
patients had failed treatment. Thus, whether the patients
had fairly large sized necks or not did not seem to make a
difference.
Your last question concerned the concentration and
filling, essentially the volume of that pseudoaneurysm with
a similar volume of dilute thrombin. Again, it is a theoret-
ical consideration: we have no empiric scientific data.
However, our feeling is that, with a high flow vessel going
by the pseudoaneurysm, if there is a dilute concentration
of thrombin being exposed to that artery, there is a high-
er wash-out effect as opposed to putting in a higher con-
centration. Again, that is our concern. We have not had
any complications. And I think the fact that the pseudoa-
neurysms that we have been treating are associated with
the femoral artery has been the main reason why we have
been able to get away with that. I do not think that we
would do the same procedure on a brachial artery
pseudoaneurysm. That is a different vessel, and it has a dif-
ferent biology.
Dr Krish Soundararajan (New York, NY). I enjoyed
your presentation. I would like to bring your attention to an
interesting finding in our study on anastamotic pseudo-
aneurysms in the carotid arteries of rats, the report of which
has been accepted for publicaton in the Journal of Vascular
Surgery.
Immunohistochemical staining results showed tissue
factor, which is actually a procoagulant, in the adventitial
aspect of the pseudoaneurysm wall and a “pseudointima”
on the luminal surface. On the basis of this, we hypothe-
size that compression therapy may cause closure of the
pseudoaneurysm, not only with stasis, but also with the
rupture of the inner layer and the exposure of the tissue
factor to blood.
If this hypothesis could be studied further, we could
inject tissue factor for the treatment of pseudoaneurysms
in the future. This could be particularly advantageous in
patients who may have had antibodies develop to previ-
ously applied topical thrombin.
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I wonder whether you screened the patients in your
study for previous therapy with thrombin. Would you
expect such prior exposure to thrombin to cause any adverse
reactions?
Dr Taylor. Thank you. We did not screen our patients
for whether they had previously undergone thrombin
injection. Clearly, as more and more people undergo
treatment with this technique, the potential for the
development of antibodies and for anaphylactic or aller-
gic reactions with thrombin is a potential complication.
Interestingly, thrombin is rapidly degraded once it is in
the arterial circulation. However, it needs to be a con-
sideration, though, because of the fact that thrombin is a
protein.
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